Trials / Terminated
TerminatedNCT01969123
Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 474 (actual)
- Sponsor
- FORUM Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 55 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of 2 fixed doses of EVP-6124 compared to placebo for 26 weeks in subjects with mild to moderate Alzheimer's disease currently receiving stable treatment or previously treated with an acetylcholinesterase inhibitor.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Drug: EVP-6124 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2013-10-25
- Last updated
- 2016-05-03
Locations
82 sites across 12 countries: United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Poland, South Africa, South Korea, Spain
Source: ClinicalTrials.gov record NCT01969123. Inclusion in this directory is not an endorsement.